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This document summarizes the rationale, equipment, measurement, and protocol procedures for 
the medication inventories collected during the Wave V in-home biomarker exam. It also 
documents the protocol for assigning therapeutic classes to those medications. Whenever 
possible, data collection and methods in Wave V mirrored those of Wave IV to ensure 
comparability of data between waves. This document is one in a set of Wave V user guides. The 
following user guides are also available to describe protocols for other biological measures in 
Wave V: 
 Anthropometric Measures 
 Cardiovascular Measures 
 Cardiovascular Measures: Baroreflex Sensitivity, & Hemodynamic Recovery 
 Measures of Glucose Homeostasis 
 Measures of Inflammation and Immune Function 
 Measures of Lipids 
 Measures of Renal Function 
 
This research uses data from Add Health, a program project directed by Kathleen Mullan Harris 
and designed by J. Richard Udry, Peter S. Bearman, and Kathleen Mullan Harris at the 
University of North Carolina at Chapel Hill, and funded by grant P01-HD31921 from the Eunice 
Kennedy Shriver National Institute of Child Health and Human Development, with cooperative 
funding from 23 other federal agencies and foundations. We gratefully acknowledge Carolyn 
Halpern, Nancy Dole, Joyce Tabor, and Sarah Dean for their dedication to the quality of the Add 
Health data in this document. Information on how to obtain the Add Health data files is available 
on the Add Health website (http://www.cpc.unc.edu/addhealth).  
 
 
Citations of this Add Health User Guide should use the following format: 
Whitsel, EA, Angel R, O’Hara R, Qu L, Carrier K, Harris K. Add Health Wave V Documentation: Medication Use, 
2019; Available from :http://www.cpc.unc.edu/projects/addhealth/data/guides/ or doi.org/10.17615/yfnj-xw14 
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1. Introduction 
 
Data on respondent use of prescription and select over-the-counter (aspirin-containing and non-
steroidal anti-inflammatory) medications were collected during the Wave V in-home exam. The 
process of collecting the prescription medication data, therapeutically classifying the prescription 
medications, and structuring a file of the therapeutic classifications for dissemination to users is 
described below.  
2. Collection of Prescription and Over-the-Counter Medication Use Data 
 
All data were collected during in-home visits performed by field examiners from two Add 
Health data collection partners: Examination Management Services, Inc. (2016-2017) and 
Hooper Holmes, Inc. (2018-2019). All examiners were trained and certified using a custom 
program specific to the Add Health protocol. Examiners used a 7” Samsung Galaxy Tab 4 tablet 
to record and later transmit their data. An Add Health data collection application (Open Data Kit 
or ODK) installed on the tablet guided the examiner through the home visit protocol. In addition, 
each examiner received a series of job aids, both on paper and on the tablet, to serve as quick 
reference guides when completing the protocol. Each tablet also contained an in depth Add 
Health training manual that could be accessed at any time. 
 
2.1 Initial Contact 
 
During a phone conversation confirming the interview appointment date and time, the field 
examiner notified the respondent that information on use of medications would be collected at 
the home visit. The examiner also suggested that it would help to have their medications handy at 
that time of the visit so they could be recorded properly. Doing so also alerted the respondent to 
bring medication containers to the visit if it was not conducted at their residence. 
 
2.2 Home Visit 
 
Medication data were collected during the home visit prompted by the ODK application on the 
tablet. The prescription medication inventory was collected after anthropometry and blood 
pressure measures, but before venous blood collection. The questions followed a preface read by 
the examiner to the respondent: 
 
“When we scheduled this visit, we said we would like to record all prescription 
medications that you have used in the past four weeks. These medications include solid 
and non-solid formulations that can be swallowed, inhaled, applied to the skin or hair, 
injected, implanted, or placed in the ears, eyes, nose, mouth, or any other part of the 
body.” 
 
This preface was followed by Question 67: 
 
“Have you taken any prescription medications in the last four weeks?” 
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If the respondent answered “Yes”, the examiner was presented with the following instruction: 
 
“If the exam is being conducted in the respondent’s home or the medications are conveniently 
available (e.g., in a purse) ask the respondent to assemble the medications or their containers 
now so that you can record information about them. If the respondent is unable or unwilling to 
assemble then now, ask him/her to list them from memory.” 
 
The examiner recorded whether the respondent presented each medication or its container at the 
visit or if they listed each medication name from memory.  Next, the examiner typed the name of  
each medication (up to fifty) into the tablet (Exhibit 1).  
 
            Exhibit 1          Exhibit 2 
 
As the examiner began typing each medication name, a look-up list of medications with identical 
or similar names was displayed on screen. The look-up list was based on a medication 
information and classification database (Multum LexiconTM, Cerner Multum, Inc.; Denver, CO) 
created by excerpting all generic and brand names included in the most current quarterly update. 
All tablets automatically detected and downloaded quarterly updates on Wi-Fi connection. 
 
The examiner had the choice of selecting medication names from the look-up list that “included” 
or “started with” the text that the examiner entered.  The examiner highlighted and selected the 
name on the look-up list that matched each medication. In the absence of an identical match on 
the look-up list, the examiner manually entered the unmatched name into a free-text data entry 
field. When all prescription medications were entered, the examiner “Saved List to Survey” 
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(Exhibit 2), thereby importing all entered prescription medications into the main ODK 
questionnaire database. 
 
After the prescription medications were inventoried, the examiner then asked the respondent two 
questions about whether they had taken either over-the-counter (OTC) aspirin-containing 
medications or OTC anti-inflammatory medications in the past 24 hours. 
 
Question 69: 
 
 “In addition to the prescription medicines that I just asked about, have you taken any over-
the-counter (OTC) aspirin or aspirin-containing medications including cold and allergy 
medications or headache powders in the past 24 hours? Some examples of these are: Anacin, 
Aspirin, B.C., Backache Relief Extra Strength, Bayer, Excedrin, Goody’s Pain Relief, Pain 
Reliever Extra Strength, or Vanquish. Please DO NOT include any acetaminophen or anti-
inflammatory medicines such as: Advil, Aleve, Ibuprofen, Midol, Motrin, or Tylenol.” 
 
Question 70: 
 
“In the past 24 hours, have you taken other OTC anti-inflammatory medications? Common 
examples include: Advil, Aleve, Ibuprofen, Midol, Motrin, Naproxen, or Nuprin. 
Medications NOT to include: Anacin, Aspirin, B.C., Backache Relief Extra Strength, Bayer, 
Excedrin, Goody’s Pain Relief, Pain Reliever Extra Strength, or Vanquish” 
 
The respondent had the option of answering yes, no, or don’t know to these two questions and 
affirmative answers have been captured in a combined variable (H5OTC24).  
 
3. Therapeutic Classification of Prescription Medications (H5SET1 – H5SET4) 
 
In 2019, a contract allowing for therapeutic classification of the prescription medications in the 
look-up list using an updated version of the Multum LexiconTM (Cerner Multum, Inc.; Denver, 
CO) was executed. Of the 7,290 prescription medications reported by respondents, 27 (< 1%) 
could not be automatically assigned to a therapeutic class using this database. A general internist 
and cardiovascular epidemiologist with expertise in medication classification manually assigned 
therapeutic classes to 26 of the 27 prescription medications using two on-line coding databases 
(Lexi- Comp® On-LineTM, Lexi-Comp®, Inc.; Hudson, OH and MICROMEDEX® 1.0, 
Thomson Reuters Healthcare, Inc; Philadelphia, PA). The Wave V medication file therefore 
contains the therapeutic class for 7,289 prescription medications (Appendix 1).   
 
In the data file, the nine-digit therapeutic classification codes associated with each prescription 
medication include a hierarchical series of up to three, three-digit codes representing, from left to 
right, the (general) therapeutic class, the (more specific) therapeutic subclass, and (most specific) 
therapeutic subgroup. For example, a prescription medication coded 001-009-161 is in the anti-
infective class, cephalosporins subclass, and third generation cephalosporins subgroup. A 
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prescription medication coded 001-018-*** is in the anti-infective class and aminoglycosides 
subclass. In other words, three, right-sided asterisks (***) in the nine-digit code indicate that 
subgrouping was impossible and six (***-***) indicate that both subclassification and 
subgrouping were impossible. A prescription medication coded 998-998-998 indicates that 
classification of the medication was impossible.  A prescription medication coded 999-999-999 
indicates that the respondent reported taking a prescription medication(s), but the medication(s) 
was not entered into the tablet. 
 
Because the study did not collect indications for treatment and some prescription medications are 
used on- or off-label to treat a variety of conditions, each prescription medication may be 
associated with up to four unique, nine-digit therapeutic classification codes, i.e. Sets 1-4.  
4. Key Therapeutic Classes of Prescription Medications 
 
Use of a prescription medication in the past 4 weeks in one or more of the listed therapeutic 
classes was assigned a value of 1.  Non-use of a prescription medication in the past four weeks in 
one of the listed therapeutic classes was assigned a value of 0. Therapeutically classified use of 
prescription medication in particular classes may confound biomarker-based estimates of disease 
prevalence or risk. For example, use of anti-hypertensive medications may confound blood 
pressure-based estimates of hypertension prevalence or cardiovascular disease risk. However, the 
following (1,0) classifications should be used cautiously in the investigation or control of 
potential confounding, because selection biases often threaten the study of non-randomized 
medication exposures. 
 
4.1 Antihypertensive Medication Use (H5AHT) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
 
Class Label Variable 
040-042-xxx Angiotensin converting enzyme (ACE) inhibitors 
H5AHT 
040-043-xxx  Anti-adrenergic agents (peripherally acting) 
040-044-xxx  Anti-adrenergic agents (centrally acting) 
040-047-xxx  Beta-adrenergic blocking agents 
040-048-xxx  Calcium channel blocking agents 
040-049-156  Thiazide diuretics 
040-053-xxx  Vasodilators 
040-055-xxx  Antihypertensives 
040-056-xxx  Angiotensin II (AT2) inhibitors 
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4.2 Antihyperlipidemic Medication Use (H5C_MED2) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
 
Class Label Variable 
358-019-173  HMG-CoA reductase inhibitors 
H5C_MED2 
358-019-174  Miscellaneous antihyperlipidemic agents  
358-019-241  Fibric acid derivatives  
358-019-252  Bile acid sequestrants  
358-019-316  Cholesterol absorption inhibitors  
358-019-317  Antihyperlipidemic combinations 
358-019-484  PCSK9 inhibitors 
 
 
4.3 Antidiabetic Medication Use (H5C_MED) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
 
Class Label Variable 
358-099-***  Antidiabetic agents 
H5C_MED 
358-099-213  Sulfonylureas 
358-099-214  Non-sulfonylureas 
358-099-215  Insulin 
358-099-216  Alpha-glucosidase inhibitors 
358-099-271  Thiazolidinediones   
358-099-282  Meglitinides   
358-099-309  Miscellaneous antidiabetic agents   
358-099-314  Antidiabetic combinations   
358-099-371  Dipeptidyl peptidase 4 inhibitors  
358-099-372  Amylin analogs  
358-099-373  Incretin mimetics  
358-099-458  SGLT-2 inhibitors 
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4.4 Anti-Inflammatory Medication Use (H5CRP1 – H5CRP8) 
Respondents used ≥ 1 medication identified by ≥ 1 of the following questions, coded 
therapeutic classes, or active ingredients: 
 
Question / Class Label Variable 
Q069=yes  
Q070=yes 
Salicylate past 24 hours or 
Non-Steroidal Anti-Inflammatory Drug 
(NSAID) past 24 hours 
H5CRP1 
057-058-061  
057-058-062  
 
NSAIDs past 4 weeks or  
Salicylate past 4 weeks or 
Any oral medication that contains NSAID or 
Salicylate as an active ingredient1 in a 
combination medication past 4 weeks 
H5CRP2 
057-058-278  Cyclooxygenase-2 (COX-2) Inhibitor past 4 
weeks H5CRP3 
122-130-296  Inhaled Corticosteroids past 4 weeks H5CRP4 
097-098-300  
097-098-301  
Corticotropin or 
Glucocorticoid past 4 weeks H5CRP5 
105-192-***  
105-270-***  
Antirheumatic or 
Antipsoriatic past 4 weeks H5CRP6 
254-104-***  
254-257-***  
Immunosupressive agents or 
Immunosuppressive monoclonal antibodies 
past 4 weeks 
H5CRP7 
Any of the above Any of the above anti-inflammatories H5CRP8 
 
1 Active Ingredients: 
 
NSAIDS   
• Bromfenac • Indomethacin • Naproxen 
• Dicloenac • Ketoprofen • Oxaprozin 
• Diflunisal • Ketorolac • Piroxicam 
• Etodolac • Meclofenamate • Sulindac 
• Fenoprofen • Mefenamic Acid • Tolmetin 
• Flurbiprofen • Meloxicam  
• Ibuprofen • Nabumetone  
 
Salicylates   
• Aspirin • Magnesium salicylate • Sodium salicylate 
• Choline salicylate • Salsalate • Thiosalicylate 
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4.5 Narcotic Medication Use (H5NARC) 
Respondents used ≥ 1 opioid-containing prescription medication in ≥ 1 of the following 
coded therapeutic classes: 
 
Class Label Variable 
057-058-060  Narcotic analgesics 
H5NARC 
057-058-191  Narcotic analgesic combinations 
057-073-179  Skeletal muscle relaxant combinations 
122-124-*** Antitussives 
122-132-*** Upper respiratory combinations 
 
--and-- 
 
the prescription medication contained ≥ 1 of the following active ingredients:  
 
• Alfentanil • Buprenorphine • Butorphanol 
• Codeine • Dezocine • Dihydrocodeine 
• Fentanyl • Hydrocodone • Hydromorphone 
• Levomethadyl • Levorphanol • Meperidine 
• Methadone • Morphine • Nalbuphine 
• Opium • Oxycodone • Oxymorphone 
• Pentazocine • Propoxyphene • Remifentanil 
• Sufentanil • Tapentadol • Tramadol 
 
 
4.6 Antidepressant Medication Use (H5AD_X, where X is defined in Exhibit 4) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
   
Class Label Variable 
242-251-079 Psychotherapeutic combinations  H5AD_CMB 
242-249-076 Miscellaneous antidepressants  H5AD_MSC 
242-249-208 Selective serotonin reuptake inhibitors  H5AD_SRI 
242-249-209 Tricyclic antidepressants  H5AD_TRI 
242-249-250 Monoamine oxidase inhibitors  H5AD_MOI 
242-249-306 Phenylpiperazine antidepressants  H5AD_PHE 
242-249-307 Tetracyclic antidepressants  H5AD_TET 
242-249-308 Selective serotonin norepinephrine reuptake inhibitors H5AD_SNR 
Any of the above Any of the above antidepressants H5AD_ANY 
 
 
4.7 Antipsychotic Medication Use (H5APS) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
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classes: 
 
Class Label Variable 
242-251-079  Psychotherapeutic combinations  
H5APS 
242-251-077  Miscellaneous antipsychotic agents  
242-251-210  Phenothiazine antipsychotics  
242-251-280  Thioxanthenes  
242-251-341  Atypical antipsychotics 
 
 
4.8 Anxiolytic, Sedative or Hypnotic Medication Use (H5ASH) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
 
Class Label Variable 
057-067-068  Barbituates  
H5ASH 057-067-069  Benzodiazepines  
057-067-070  Miscellaneous anxiolytics, sedatives and hypnotics 
 
4.9 Anticonvulsant Medication Use (H5ACO) 
Respondents used ≥ 1 prescription medication in ≥ 1 of the following coded therapeutic 
classes: 
 
Class Label Variable 
057-064-199  Hydantoin anticonvulsants   
H5ACO 
057-064-200  Succinimide anticonvulsants   
057-064-201  Barbiturate anticonvulsants   
057-064-202  Oxazolidinedione anticonvulsants   
057-064-203  Benzodiazepine anticonvulsants   
057-064-204  Miscellaneous anticonvulsants   
057-064-311  Dibenzazepine anticonvulsants   
057-064-345  Fatty acid derivative anticonvulsants  
057-064-346  Gamma-aminobutyric acid reuptake inhibitors  
057-064-347  Gamma-aminobutyric acid analogs   
057-064-348  Triazine anticonvulsants   
057-064-349  Carbamate anticonvulsants   
057-064-350  Pyrrolidine anticonvulsants   
057-064-351  Carbonic anhydrase inhibitor anticonvulsants  
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057-064-352  Urea anticonvulsants   
057-064-446  Neuronal potassium channel openers  
057-064-456  α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor antagonists   
 
5. Quality Control of the Prescription Medication Data 
 
Within a race/ethnicity- and sex-stratified random sample of 112 Add Health respondents among 
whom prescription medications were inventoried twice, on average 14.1 (95% confidence 
interval [CI]: 13.0-15.3) days apart, typically by the same examiner and at approximately the 
same time of day, the agreement (95% CI) between therapeutic classifications was 85% (79%-
92%), kappa coefficient (95% CI) = 0.82 (0.71-0.93).  The observations suggest that in-home 
prescription medication data are reliable at Add Health Wave V. 
 
Of the 12,300 Add Health respondents who completed the Wave V survey, 5,206 also completed 
an in-home exam.  Among them, prescription medication use was thereby inventoried twice 
(during the Wave V survey and in-home exam), albeit using somewhat different methods 
administered on average (95% confidence interval [CI]) 8.1 (7.9,8.3) months apart.  The 
agreement (95% CI) between therapeutic classifications was nonetheless 64% (63%-65%) and 
kappa coefficient (95% CI) was 0.62 (0.60-0.64).  The observations suggest that within Add 
Health Wave V, prescription medication data are comparable across the survey and in-home 
exam. 
 
 
6. The Medication Data File (meds5.xpt)   
 
6.1 Hierarchical Structure 
 
The structure of the disseminated medication data file is hierarchical.  This means that it is a 
medication-level data file, where each therapeutically classified prescription medication and OTC 
medication appear in the data as single observations.  Therefore, if a respondent reported taking 
more than one medication, the respondent’s identifying number (in the AID variable) will appear 
in the data file more than once.  Alternatively, the respondent’s identifying number will appear in 
the data file just one time on a single observation if:  (a) the respondent reported using just one 
medication, (b) the respondent reported not taking any medications, (c) the respondent refused to 
answer the medication questions, or (d) the exam was terminated before the medication 
questions could be asked of the respondent.    
 
6.2 Respondent-Level Overview of the Medication Responses 
 
Given the complex hierarchical structure of the data file, this section provides an overview, at 
the respondent-level, of the medications reported by the respondents:   
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Of the 5,381 respondents who participated in the home visit, 3,327 (61.8%) took either 
prescription medications or OTC medications, 2,028 (37.7%) took no medications, 3 (<1%) 
refused to answer, and 23 (< 1%) were not asked medication questions because the exam had 
been terminated beforehand. 
 
Of the 3,327 respondents who took medications, 1,940 (58.3%) took prescription medications 
only, 799 (24%) took both prescription and OTC medications, and 588 (17.7%) took OTC 
medications only.  
 
From the 2,739 respondents who had taken prescription medications, a total of 7,290 prescription 
medications were presented/listed.  Of these prescription medications, 4,813 (66.0%) were 
physically presented and 2,477 (34.0%) were recalled from memory. 
 
6.3 The Variables 
 
The medication data file includes the variables below, which are described in the corresponding 
codebook documentation that also contains frequencies.  Please note, however, that the 
frequencies reported in the codebook are at the medication-level and not at the respondent-level. 
 
Variable Name Variable Label 
AID Respondent Identifier 
H5EXDATE Date of Exam (YYYYMMDD)                
H5EXCOMP Flag that indicates if the respondent completed the exam 
H5MEDUSE Medications used by the respondent, if any 
H5SET1 – H5SET4   Therapeutic Classification – Set #1 – #4  
H5OTC24 Type of OTC medication taken in the past 24 hours   
H5MEDTOT  # of Prescription Medications inventoried       
H5MEDMEM  # of Prescription Medications recalled from memory  
H5MEDMAN  # of Prescription Medications entered manually  
H5AHT     Antihypertensive                  
H5C_MED2  Antihyperlipidemic              
H5C_MED   Antidiabetic                    
H5CRP1    CRP - NSAID/salicylate (24 hr)  
H5CRP2    CRP - NSAID/salicylate (4 wks)  
H5CRP3    CRP - Cox-2 inhibitor          
H5CRP4    CRP - Inhaled corticosteroid   
H5CRP5    CRP - Corticotropin/Glucocorticoid  
H5CRP6    CRP - Antirheumatic/Antipsoriatic  
H5CRP7    CRP - Immunosuppressive         
H5CRP8    Anti-Inflammatory               
H5NARC    Narcotic                        
H5AD_ANY  Antidepressant                  
H5AD_CMB  AD - Pyschotherapeutic combinations  
H5AD_MSC  AD - Miscellaneous              
H5AD_SRI  AD - Selective serotonin reuptake inhibitors 
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H5AD_TRI  AD - Tricyclic                  
H5AD_MOI  AD - Monoamine oxidase inhibitors      
H5AD_PHE  AD - Phenylpiperazine           
H5AD_TET  AD - Tetracyclic                
H5AD_SNR  AD - Selective serotonin norepinephrine reuptake inhibitors 
H5APS     Antipsychotic                   
H5ASH     Anxiolytic/Sedative/Hypnotic    
H5ACO     Anticonvulsant 
 
Given all of the former complexities, Add Health users possessing no to little prior 
experience working with medication data are strongly advised to collaborate with a health 
care professional familiar with the challenges and pitfalls associated with doing so. 
 
Appendix 1 
 
Table. Therapeutic Classification Codes 
Code Name 
001 anti-infectives 
002 amebicides 
003 anthelmintics 
004 antifungals 
005 antimalarial agents 
006 antituberculosis agents 
007 antiviral agents 
008 carbapenems 
009 cephalosporins 
010 leprostatics 
011 macrolide derivatives 
012 miscellaneous antibiotics 
013 penicillins 
014 quinolones 
015 sulfonamides 
016 tetracyclines 
017 urinary anti-infectives 
018 aminoglycosides 
019 antihyperlipidemic agents 
020 antineoplastics 
021 alkylating agents 
022 antineoplastic antibiotics 
023 antimetabolites 
024 antineoplastic hormones 
025 miscellaneous antineoplastics 
026 mitotic inhibitors 
027 radiopharmaceuticals 
028 biologicals 
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Table. Therapeutic Classification Codes 
Code Name 
030 antitoxins and antivenins 
031 bacterial vaccines 
032 colony stimulating factors 
033 immune globulins 
034 in vivo diagnostic biologicals 
036 erythropoiesis-stimulating agents 
038 viral vaccines 
040 cardiovascular agents 
041 agents for hypertensive emergencies 
042 angiotensin converting enzyme (ACE) inhibitors 
043 antiadrenergic agents, peripherally acting 
044 antiadrenergic agents, centrally acting 
045 antianginal agents 
046 antiarrhythmic agents 
047 beta-adrenergic blocking agents 
048 calcium channel blocking agents 
049 diuretics 
050 inotropic agents 
051 miscellaneous cardiovascular agents 
052 peripheral vasodilators 
053 vasodilators 
054 vasopressors 
055 antihypertensive combinations 
056 angiotensin II inhibitors 
057 central nervous system agents 
058 analgesics 
059 miscellaneous analgesics 
060 narcotic analgesics 
061 nonsteroidal anti-inflammatory agents 
062 salicylates 
063 analgesic combinations 
064 anticonvulsants 
065 antiemetic/antivertigo agents 
066 antiparkinson agents 
067 anxiolytics, sedatives, and hypnotics 
068 barbiturates 
069 benzodiazepines 
070 miscellaneous anxiolytics, sedatives and hypnotics 
071 CNS stimulants 
072 general anesthetics 
073 muscle relaxants 
074 neuromuscular blocking agents 
076 miscellaneous antidepressants 
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Table. Therapeutic Classification Codes 
Code Name 
077 miscellaneous antipsychotic agents 
079 psychotherapeutic combinations 
080 miscellaneous central nervous system agents 
081 coagulation modifiers 
082 anticoagulants 
083 antiplatelet agents 
084 heparin antagonists 
085 miscellaneous coagulation modifiers 
086 thrombolytics 
087 gastrointestinal agents 
088 antacids 
089 anticholinergics/antispasmodics 
090 antidiarrheals 
091 digestive enzymes 
092 gallstone solubilizing agents 
093 GI stimulants 
094 H2 antagonists 
095 laxatives 
096 miscellaneous GI agents 
097 hormones/hormone modifiers 
098 adrenal cortical steroids 
099 antidiabetic agents 
101 sex hormones 
102 contraceptives 
103 thyroid hormones 
104 immunosuppressive agents 
105 miscellaneous agents 
106 antidotes 
107 chelating agents 
108 cholinergic muscle stimulants 
109 local injectable anesthetics 
110 miscellaneous uncategorized agents 
111 psoralens 
112 radiocontrast agents 
113 genitourinary tract agents 
115 nutritional products 
116 iron products 
117 minerals and electrolytes 
118 oral nutritional supplements 
119 vitamins 
120 vitamin and mineral combinations 
121 intravenous nutritional products 
122 respiratory agents 
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Table. Therapeutic Classification Codes 
Code Name 
123 antihistamines 
124 antitussives 
125 bronchodilators 
126 methylxanthines 
127 decongestants 
128 expectorants 
129 miscellaneous respiratory agents 
130 respiratory inhalant products 
131 antiasthmatic combinations 
132 upper respiratory combinations 
133 topical agents 
134 anorectal preparations 
135 antiseptic and germicides 
136 dermatological agents 
137 topical anti-infectives 
138 topical steroids 
139 topical anesthetics 
140 miscellaneous topical agents 
141 topical steroids with anti-infectives 
143 topical acne agents 
144 topical antipsoriatics 
146 mouth and throat products 
147 ophthalmic preparations 
148 otic preparations 
149 spermicides 
150 sterile irrigating solutions 
151 vaginal preparations 
153 plasma expanders 
154 loop diuretics 
155 potassium-sparing diuretics 
156 thiazide and thiazide-like diuretics 
157 carbonic anhydrase inhibitors 
158 miscellaneous diuretics 
159 first generation cephalosporins 
160 second generation cephalosporins 
161 third generation cephalosporins 
162 fourth generation cephalosporins 
163 ophthalmic anti-infectives 
164 ophthalmic glaucoma agents 
165 ophthalmic steroids 
166 ophthalmic steroids with anti-infectives 
167 ophthalmic anti-inflammatory agents 
168 ophthalmic lubricants and irrigations 
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Table. Therapeutic Classification Codes 
Code Name 
169 miscellaneous ophthalmic agents 
170 otic anti-infectives 
171 otic steroids with anti-infectives 
172 miscellaneous otic agents 
173 HMG-CoA reductase inhibitors (statins) 
174 miscellaneous antihyperlipidemic agents 
175 protease inhibitors 
176 NRTIs 
177 miscellaneous antivirals 
178 skeletal muscle relaxants 
179 skeletal muscle relaxant combinations 
180 adrenergic bronchodilators 
181 bronchodilator combinations 
182 androgens and anabolic steroids 
183 estrogens 
184 gonadotropins 
185 progestins 
186 sex hormone combinations 
191 narcotic analgesic combinations 
192 antirheumatics 
193 antimigraine agents 
194 antigout agents 
195 5HT3 receptor antagonists 
196 phenothiazine antiemetics 
197 anticholinergic antiemetics 
198 miscellaneous antiemetics 
199 hydantoin anticonvulsants 
200 succinimide anticonvulsants 
201 barbiturate anticonvulsants 
202 oxazolidinedione anticonvulsants 
203 benzodiazepine anticonvulsants 
204 miscellaneous anticonvulsants 
205 anticholinergic antiparkinson agents 
208 SSRI antidepressants 
209 tricyclic antidepressants 
210 phenothiazine antipsychotics 
211 platelet aggregation inhibitors 
212 glycoprotein platelet inhibitors 
213 sulfonylureas 
214 biguanides 
215 insulin 
216 alpha-glucosidase inhibitors 
217 bisphosphonates 
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218 alternative medicines 
219 nutraceutical products 
220 herbal products 
222 penicillinase resistant penicillins 
223 antipseudomonal penicillins 
224 aminopenicillins 
225 penicillins/beta-lactamase inhibitors 
226 natural penicillins 
227 NNRTIs 
228 adamantane antivirals 
229 purine nucleosides 
230 aminosalicylates 
231 thiocarbamide derivatives 
232 rifamycin derivatives 
233 streptomyces derivatives 
234 miscellaneous antituberculosis agents 
235 polyenes 
236 azole antifungals 
237 miscellaneous antifungals 
238 antimalarial quinolines 
239 miscellaneous antimalarials 
240 lincomycin derivatives 
241 fibric acid derivatives 
242 psychotherapeutic agents 
243 leukotriene modifiers 
244 nasal lubricants and irrigations 
245 nasal steroids 
246 nasal antihistamines and decongestants 
247 nasal preparations 
248 topical emollients 
249 antidepressants 
250 monoamine oxidase inhibitors 
251 antipsychotics 
252 bile acid sequestrants 
253 anorexiants 
254 immunologic agents 
256 interferons 
261 heparins 
262 coumarins and indanediones 
263 erectile dysfunction agents 
264 urinary antispasmodics 
265 urinary pH modifiers 
266 miscellaneous genitourinary tract agents 
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267 ophthalmic antihistamines and decongestants 
268 vaginal anti-infectives 
269 miscellaneous vaginal agents 
270 antipsoriatics 
271 thiazolidinediones 
272 proton pump inhibitors 
273 lung surfactants 
274 beta blockers, cardioselective 
275 beta blockers, non-cardioselective 
276 dopaminergic antiparkinsonism agents 
277 5-aminosalicylates 
278 cox-2 inhibitors 
279 gonadotropin-releasing hormone and analogs 
280 thioxanthenes 
281 neuraminidase inhibitors 
282 meglitinides 
283 thrombin inhibitors 
284 viscosupplementation agents 
285 factor Xa inhibitors 
286 mydriatics 
287 ophthalmic anesthetics 
288 5-alpha-reductase inhibitors 
289 antihyperuricemic agents 
290 topical antibiotics 
291 topical antivirals 
292 topical antifungals 
293 glucose elevating agents 
295 growth hormones 
296 inhaled corticosteroids 
297 mucolytics 
298 mast cell stabilizers 
299 anticholinergic bronchodilators 
300 corticotropin 
301 glucocorticoids 
302 mineralocorticoids 
303 agents for pulmonary hypertension 
304 macrolides 
305 ketolides 
306 phenylpiperazine antidepressants 
307 tetracyclic antidepressants 
308 SSNRI antidepressants 
310 echinocandins 
311 dibenzazepine anticonvulsants 
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312 cholinergic agonists 
313 cholinesterase inhibitors 
314 antidiabetic combinations 
315 glycylcyclines 
316 cholesterol absorption inhibitors 
317 antihyperlipidemic combinations 
318 insulin-like growth factor 
319 vasopressin antagonists 
320 smoking cessation agents 
321 ophthalmic diagnostic agents 
322 ophthalmic surgical agents 
324 antineoplastic interferons 
325 sclerosing agents 
327 antiviral combinations 
328 antimalarial combinations 
329 antituberculosis combinations 
330 antiviral interferons 
332 radiologic adjuncts 
333 miscellaneous iodinated contrast media 
334 lymphatic staining agents 
335 magnetic resonance imaging contrast media 
336 non-iodinated contrast media 
337 ultrasound contrast media 
338 diagnostic radiopharmaceuticals 
339 therapeutic radiopharmaceuticals 
340 aldosterone receptor antagonists 
341 atypical antipsychotics 
342 renin inhibitors 
345 fatty acid derivative anticonvulsants 
346 gamma-aminobutyric acid reuptake inhibitors 
347 gamma-aminobutyric acid analogs 
348 triazine anticonvulsants 
349 carbamate anticonvulsants 
350 pyrrolidine anticonvulsants 
351 carbonic anhydrase inhibitor anticonvulsants 
352 urea anticonvulsants 
353 anti-angiogenic ophthalmic agents 
354 H. pylori eradication agents 
355 functional bowel disorder agents 
356 serotoninergic neuroenteric modulators 
357 growth hormone receptor blockers 
358 metabolic agents 
359 peripherally acting antiobesity agents 
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360 lysosomal enzymes 
361 miscellaneous metabolic agents 
362 chloride channel activators 
363 probiotics 
364 antiviral chemokine receptor antagonist 
366 integrase strand transfer inhibitor 
368 non-ionic iodinated contrast media 
369 ionic iodinated contrast media 
370 otic steroids 
371 dipeptidyl peptidase 4 inhibitors 
372 amylin analogs 
373 GLP-1 receptor agonists 
374 cardiac stressing agents 
375 peripheral opioid receptor antagonists 
376 radiologic conjugating agents 
377 prolactin inhibitors 
378 drugs used in alcohol dependence 
379 fifth generation cephalosporins 
380 topical debriding agents 
381 topical depigmenting agents 
382 topical antihistamines 
383 antineoplastic detoxifying agents 
384 platelet-stimulating agents 
385 group I antiarrhythmics 
386 group II antiarrhythmics 
387 group III antiarrhythmics 
388 group IV antiarrhythmics 
389 group V antiarrhythmics 
390 hematopoietic stem cell mobilizer 
392 otic anesthetics 
393 cerumenolytics 
394 topical astringents 
395 topical keratolytics 
397 multikinase inhibitors 
398 BCR-ABL tyrosine kinase inhibitors 
399 CD52 monoclonal antibodies 
400 CD33 monoclonal antibodies 
401 CD20 monoclonal antibodies 
402 VEGF/VEGFR  inhibitors 
403 mTOR inhibitors 
404 EGFR inhibitors 
405 HER2 inhibitors 
406 glycopeptide antibiotics 
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407 inhaled anti-infectives 
408 histone deacetylase inhibitors 
409 bone resorption inhibitors 
410 adrenal corticosteroid inhibitors 
411 calcitonin 
412 uterotonic agents 
413 antigonadotropic agents 
414 antidiuretic hormones 
415 miscellaneous bone resorption inhibitors 
416 somatostatin and somatostatin analogs 
417 selective estrogen receptor modulators 
418 parathyroid hormone and analogs 
419 gonadotropin-releasing hormone antagonists 
420 antiandrogens 
422 antithyroid agents 
423 aromatase inhibitors 
424 estrogen receptor antagonists 
426 synthetic ovulation stimulants 
427 tocolytic agents 
428 progesterone receptor modulators 
430 anticholinergic chronotropic agents 
431 anti-CTLA-4 monoclonal antibodies 
432 vaccine combinations 
433 catecholamines 
435 selective phosphodiesterase-4 inhibitors 
437 immunostimulants 
438 interleukins 
439 other immunostimulants 
440 therapeutic vaccines 
441 calcineurin inhibitors 
442 TNF alpha inhibitors 
443 interleukin inhibitors 
444 selective immunosuppressants 
445 other immunosuppressants 
446 neuronal potassium channel openers 
447 CD30 monoclonal antibodies 
448 topical non-steroidal anti-inflammatories 
449 hedgehog pathway inhibitors 
450 topical antineoplastics 
451 topical photochemotherapeutics 
452 CFTR modulators 
453 topical rubefacient 
454 proteasome inhibitors 
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455 guanylate cyclase-C agonists 
456 AMPA receptor antagonists 
457 hydrazide derivatives 
458 SGLT-2 inhibitors 
459 urea cycle disorder agents 
460 phosphate binders 
461 topical anti-rosacea agents 
462 allergenics 
463 protease-activated receptor-1 antagonists 
464 miscellaneous diagnostic dyes 
465 diarylquinolines 
467 ACE inhibitors with thiazides 
468 antiadrenergic agents (central) with thiazides 
469 antiadrenergic agents (peripheral) with thiazides 
470 miscellaneous antihypertensive combinations 
472 beta blockers with thiazides 
473 angiotensin II inhibitors with thiazides 
475 potassium sparing diuretics with thiazides 
476 ACE inhibitors with calcium channel blocking agents 
479 angiotensin II inhibitors with calcium channel blockers 
480 antiviral boosters 
481 NK1 receptor antagonists 
482 angiotensin receptor blockers and neprilysin inhibitors 
484 PCSK9 inhibitors 
485 NS5A inhibitors 
486 oxazolidinone antibiotics 
487 CFTR combinations 
488 anticoagulant reversal agents 
489 CD38 monoclonal antibodies 
490 peripheral opioid receptor mixed agonists/antagonists 
491 local injectable anesthetics with corticosteroids 
492 cephalosporins/beta-lactamase inhibitors 
493 anti-PD-1 monoclonal antibodies 
494 PARP inhibitors 
495 calcimimetics 
496 VMAT2 inhibitors 
497 cation exchange resins 
498 antineoplastic combinations 
499 carbapenems/beta-lactamase inhibitors 
500 PI3K inhibitors 
501 CDK 4/6 inhibitors 
502 CGRP inhibitors 
503 streptogramins 
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504 antimanic agents 
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